OMCL

Omnicell, Inc. NASDAQ

Healthcare ·Medical - Healthcare Information Services ·US · omnicell.com

$43.44

Mkt Cap $2.0B

52w Low $22.66 64.3% of range 52w High $55.00

50d MA $37.34 200d MA $36.83

P/E (TTM) 959.6x

EV/EBITDA 21.7x

P/B 1.6x

Debt/Equity 0.2x

ROE 0.2%

P/FCF 24.0x

RSI (14) —

ATR (14) —

Beta 0.86

50d MA $37.34

200d MA $36.83

Avg Volume 700.6K

About

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursi…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 28, 2026	TNS	0.33	0.55	+66.7%	45.51	+0.0%	-5.3%	-9.0%	-6.0%	-4.5%	-5.2%	—
Feb 5, 2026	TNS	0.47	0.40	-14.9%	39.08	-1.5%	-5.1%	-6.6%	-0.2%	-3.2%	-7.4%	—
Oct 30, 2025	TNS	0.36	0.51	+41.7%	33.58	+0.4%	-0.0%	-0.6%	+2.7%	+6.4%	+6.5%	—
Jul 31, 2025	TNS	0.31	0.45	+45.2%	31.01	-0.9%	-4.0%	-1.9%	-1.6%	+0.3%	+0.1%	—
May 6, 2025	TNS	0.16	0.26	+62.5%	25.66	+0.0%	-4.0%	-1.1%	+0.5%	+7.0%	+9.1%	—
Feb 6, 2025	TNS	0.57	0.60	+5.3%	39.43	+0.2%	+1.9%	+7.5%	+4.6%	+2.7%	+2.0%	—
Oct 30, 2024	TNS	0.41	0.56	+36.6%	53.05	-0.9%	-8.3%	-8.3%	-8.6%	-6.1%	-1.0%	—
Aug 1, 2024	TNS	0.16	0.51	+218.8%	38.85	+1.9%	+1.0%	+3.0%	+6.4%	+0.5%	+3.5%	—
May 2, 2024	TNS	-0.08	0.03	+137.5%	29.29	+2.0%	+2.9%	+2.4%	+3.4%	+2.3%	+3.3%	—
Feb 8, 2024	TNS	0.17	0.33	+94.1%	29.10	-3.0%	-5.8%	-0.7%	-1.7%	-4.7%	-2.7%	—
Nov 2, 2023	TNS	0.45	0.62	+37.8%	29.24	+2.0%	+4.1%	+0.9%	+5.3%	+5.7%	+3.4%	—
Aug 1, 2023	TNS	0.28	0.57	+103.6%	61.70	+1.7%	+4.7%	+3.5%	+5.3%	+5.8%	+4.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 29	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$45.51	$45.51	+0.0%	-5.3%	-9.0%	-6.0%	—	—
Apr 23	Wells Fargo	Maintains	Overweight → Overweight	—	$36.65	$36.91	+0.7%	-0.8%	+2.0%	+2.7%	+24.2%	+17.6%
Feb 6	Piper Sandler	Maintains	Overweight → Overweight	—	$39.08	$38.51	-1.5%	-5.1%	-6.6%	-0.2%	-3.2%	-7.4%
Feb 2	Benchmark	Maintains	Buy → Buy	—	$48.50	$49.09	+1.2%	+0.4%	-5.1%	-3.7%	-19.4%	-23.6%
Jan 8	KeyBanc Capital Markets	Upgrade	Sector Weight → Overweight	—	$47.45	$49.90	+5.2%	+6.6%	+6.9%	+7.9%	+8.3%	+6.9%
Jan 5	Wells Fargo	Maintains	Overweight → Overweight	—	$45.14	$45.14	+0.0%	+4.0%	+4.3%	+5.1%	+12.1%	+12.4%
Dec 9	BofA Securities	Maintains	Neutral → Neutral	—	$43.55	$44.00	+1.0%	-0.1%	+1.0%	-0.6%	+0.7%	-0.6%
Dec 9	Benchmark	Maintains	Buy → Buy	—	$43.55	$44.00	+1.0%	-0.1%	+1.0%	-0.6%	+0.7%	-0.6%
Oct 31	Benchmark	Maintains	Buy → Buy	—	$33.58	$33.72	+0.4%	-0.0%	-0.6%	+2.7%	+6.4%	+6.5%
Aug 11	Piper Sandler	Maintains	Overweight → Overweight	—	$30.83	$30.63	-0.6%	+0.0%	+2.3%	+1.7%	+2.1%	+2.8%
Jul 21	Wells Fargo	Maintains	Overweight → Overweight	—	$26.88	$27.08	+0.7%	+4.3%	+5.1%	+4.9%	+4.7%	+5.2%
Jul 14	BofA Securities	Maintains	Neutral → Neutral	—	$28.69	$28.24	-1.6%	-3.9%	-5.1%	-3.2%	-2.5%	-6.3%
May 23	BofA Securities	Maintains	Neutral → Neutral	—	$28.84	$28.33	-1.8%	-2.1%	+2.7%	+1.8%	+3.4%	+5.3%
May 23	Wells Fargo	Maintains	Overweight → Overweight	—	$28.84	$28.33	-1.8%	-2.1%	+2.7%	+1.8%	+3.4%	+5.3%
May 14	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$28.00	$29.48	+5.3%	+2.6%	+0.3%	-0.1%	-0.5%	+2.8%
May 7	Benchmark	Maintains	Buy → Buy	—	$25.66	$25.67	+0.0%	-4.0%	-1.1%	+0.5%	+7.0%	+9.1%
May 7	BofA Securities	Maintains	Neutral → Neutral	—	$25.66	$25.67	+0.0%	-4.0%	-1.1%	+0.5%	+7.0%	+9.1%
May 7	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$25.66	$25.67	+0.0%	-4.0%	-1.1%	+0.5%	+7.0%	+9.1%
Apr 17	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$30.95	$30.35	-1.9%	-2.2%	-4.2%	-3.3%	-0.8%	+0.8%
Mar 20	JP Morgan	Maintains	Neutral → Neutral	—	$34.70	$34.25	-1.3%	+0.5%	-2.2%	+1.3%	-0.7%	-0.7%
Mar 13	BofA Securities	Maintains	Neutral → Neutral	—	$33.34	$33.47	+0.4%	-3.2%	-1.0%	-0.4%	-1.2%	+4.1%
Feb 4	Benchmark	Maintains	Buy → Buy	—	$43.42	$43.06	-0.8%	+1.0%	+2.2%	-9.2%	-7.5%	-2.3%
Jan 13	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$42.28	$41.79	-1.2%	+0.1%	+0.1%	+2.0%	-0.3%	+0.7%
Jan 6	BofA Securities	Maintains	Neutral → Neutral	—	$45.32	$45.09	-0.5%	-1.3%	-4.3%	-4.9%	-6.7%	-6.6%
Nov 21	JP Morgan	Maintains	Neutral → Neutral	—	$41.82	$42.23	+1.0%	+5.5%	+9.3%	+9.9%	+8.7%	+15.9%
Oct 31	BofA Securities	Downgrade	Buy → Neutral	—	$53.05	$52.56	-0.9%	-8.3%	-8.3%	-8.6%	-6.1%	-1.0%
Oct 31	Craig-Hallum	Maintains	Buy → Buy	—	$53.05	$52.56	-0.9%	-8.3%	-8.3%	-8.6%	-6.1%	-1.0%
Oct 31	Barclays	Maintains	Equal Weight → Equal Weight	—	$53.05	$52.56	-0.9%	-8.3%	-8.3%	-8.6%	-6.1%	-1.0%
Oct 14	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$42.62	$42.85	+0.5%	+0.3%	-0.6%	-0.1%	-2.8%	-3.6%
Oct 9	Benchmark	Maintains	Buy → Buy	—	$43.04	$43.00	-0.1%	-0.2%	-2.1%	-1.0%	-0.7%	-1.5%
Aug 23	JP Morgan	Maintains	Neutral → Neutral	—	$42.52	$42.95	+1.0%	+5.4%	+6.8%	+6.8%	+6.3%	+6.4%
Aug 2	BofA Securities	Maintains	Buy → Buy	—	$38.85	$39.60	+1.9%	+1.0%	+3.0%	+6.4%	+0.5%	+3.5%
Aug 2	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$38.85	$39.60	+1.9%	+1.0%	+3.0%	+6.4%	+0.5%	+3.5%
Aug 2	Barclays	Upgrade	Underweight → Equal Weight	—	$38.85	$39.60	+1.9%	+1.0%	+3.0%	+6.4%	+0.5%	+3.5%
Jul 15	Benchmark	Maintains	Buy → Buy	—	$26.55	$26.54	-0.0%	-0.4%	+3.8%	+7.9%	+3.7%	+3.7%
May 3	Benchmark	Maintains	Buy → Buy	—	$29.29	$29.87	+2.0%	+2.9%	+2.4%	+3.4%	+2.3%	+3.3%
Apr 30	Benchmark	Maintains	Buy → Buy	—	$27.40	$26.95	-1.6%	-2.2%	-0.8%	+6.9%	+10.0%	+9.4%
Feb 9	Benchmark	Maintains	Buy → Buy	—	$29.10	$28.23	-3.0%	-5.8%	-0.7%	-1.7%	-4.7%	-2.7%
Feb 9	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$29.10	$28.23	-3.0%	-5.8%	-0.7%	-1.7%	-4.7%	-2.7%
Nov 3	Wells Fargo	Upgrade	Underweight → Equal Weight	—	$29.24	$29.82	+2.0%	+4.1%	+0.9%	+5.3%	+5.7%	+3.4%
Nov 3	BTIG	Downgrade	Buy → Neutral	—	$29.24	$29.82	+2.0%	+4.1%	+0.9%	+5.3%	+5.7%	+3.4%
Nov 3	Piper Sandler	Upgrade	Neutral → Overweight	—	$29.24	$29.82	+2.0%	+4.1%	+0.9%	+5.3%	+5.7%	+3.4%
Oct 11	KeyBanc Capital Markets	Downgrade	Overweight → Sector Weight	—	$45.81	$44.85	-2.1%	-2.4%	-6.2%	-8.0%	-7.8%	-7.5%
Oct 3	Benchmark	Maintains	Buy → Buy	—	$45.16	$44.60	-1.2%	-1.7%	-2.7%	-3.3%	-4.3%	-3.0%
Sep 26	Wells Fargo	Maintains	Underweight → Underweight	—	$48.50	$47.13	-2.8%	-6.0%	-8.0%	-6.7%	-7.1%	-6.9%
Aug 4	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$63.88	$63.88	+0.0%	+1.7%	+2.2%	+0.7%	+2.5%	+0.5%
Aug 2	Benchmark	Maintains	Buy → Buy	—	$61.70	$62.76	+1.7%	+4.7%	+3.5%	+5.3%	+5.8%	+4.2%
Aug 2	Piper Sandler	Downgrade	Overweight → Neutral	—	$61.70	$62.76	+1.7%	+4.7%	+3.5%	+5.3%	+5.8%	+4.2%
Jul 31	Benchmark	Maintains	Buy → Buy	—	$62.96	$62.96	+0.0%	+0.3%	-2.0%	+2.6%	+1.5%	+3.2%
Jul 20	Wells Fargo	Downgrade	Overweight → Underweight	—	$67.42	$65.30	-3.1%	-6.7%	-6.3%	-7.7%	-7.2%	-7.7%

Recent Filings

8-K

Omnicell Inc -- 8-K Filing

Omnicell raised its full-year 2026 non-GAAP EBITDA and EPS guidance following strong first-quarter results, while advancing customer engagement for its Titan XT and OmniSphere products.

Apr 28

8-K

Omnicell Inc -- 8-K Filing

Omnicell announced its fourth quarter and full-year 2025 financial results, demonstrating performance for the healthcare technology company focused on autonomous medication management solutions.

Feb 5

Data updated apr 26, 2026 5:21pm · Source: massive.com